Phase I trial to assess the safety and immunogenicity of xenogeneic CD20 DNA vaccination [B-cell lymphoma vaccine] with patients with B-cell lymphoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs B cell lymphoma vaccine (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions; Pharmacodynamics
- 17 Nov 2015 Biomarkers information updated
- 26 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Sep 2012 Planned end date changed from 1 Oct 2009 to 1 Oct 2014 as reported by ClinicalTrials.gov.